Exploiting Macropinocytosis Drives Redox Vulnerability to Preferentially Target Drug-Resistant Cancer
ACS Nano · 28.07.2026 · 20 (29) · 20623-20638
DOI: 10.1021/acsnano.6c04236 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 14.07.2026. Verfasst von Jin Hong Lim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gangnam Severance Hospital, Department of Surgery, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul06273, Republic of Korea. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Antineoplastic Agents, Pinocytosis, Peptides. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health and Welfare, National Research Foundation of Korea.
Abstract (Originalsprache)
Therapy-resistant cancers remain largely incurable because malignant cells acquire metabolic adaptations that sustain survival under chronic cytotoxic and oxidative stress. One such adaptation is constitutively enhanced macropinocytosis, enabling aggressive cancer cells to scavenge extracellular nutrients and maintain redox homeostasis. Here, we introduce a macropinocytosis-exploiting polymer–metal strategy that converts this metabolic dependency into a lethal vulnerability. We developed PPS02, a polyaspartic acid sodium salt-based metal complex that is preferentially internalized by cancer cells via macropinocytosis, while remaining largely excluded from normal epithelial cells. This cancer-preferential uptake enables intracellular delivery of selenomethionine and ferrous iron, resulting in intracellular H2O2 accumulation, mitochondrial reactive oxygen species overload, and activation of necroptotic cell death. Macropinocytic activity was significantly elevated in patient-derived metastatic colorectal cancer cells but remained minimal in normal colonic epithelial cells, demonstrating pronounced cancer selectivity. Accordingly, PPS02 exhibited negligible cytotoxicity toward normal colonic epithelial cells while effectively suppressing the viability of both nonmetastatic and platinum-resistant metastatic colorectal cancer cells. In patient-derived xenograft models, PPS02 induced sustained tumor regression without overt systemic toxicity under the experimental conditions, whereas cisplatin failed to control metastatic tumors and caused significant adverse effects. Collectively, these findings support macropinocytosis-driven redox imbalance as a therapeutically exploitable vulnerability and demonstrate a polymer–metal platform that preferentially induces necroptosis in drug-resistant cancer while sparing normal tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gangnam Severance Hospital, Department of Surgery, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul06273, Republic of Korea.
- Department of Internal Medicine, Institute of Gastroenterology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul06273, Republic of Korea.
- Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam13496, Republic of Korea.
- TherapeuticsNMC Corp., A-1312, 11, Beobwon-ro 11-gil, Songpa-gu, Seoul05836, Republic of Korea.
- Natural Product Informatics Research Center, KIST Gangneung Institute of Natural Products, Gangneung25451, Republic of Korea.
- Department of Surgery, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul03722, Republic of Korea.
ORCID-Profile: Hyemee Yoon, Ki Cheong Park
Förderung
- Ministry of Health and Welfare
- National Research Foundation of Korea
Zitieren
APA
Lim, J. H., Kim, Y., Kim, S. M., Choi, K. H., Park, J., Yoon, H., Park, K., Park, K. C., & Hur, C. (2026). Exploiting Macropinocytosis Drives Redox Vulnerability to Preferentially Target Drug-Resistant Cancer. ACS Nano, 20(29), 20623-20638. https://doi.org/10.1021/acsnano.6c04236
Vancouver
Lim JH, Kim Y, Kim SM, Choi KH, Park J, Yoon H, et al. Exploiting Macropinocytosis Drives Redox Vulnerability to Preferentially Target Drug-Resistant Cancer. ACS Nano. 2026;20(29):20623-20638. doi:10.1021/acsnano.6c04236
BibTeX
@article{Lim2026,
author = {Lim, Jin Hong and Kim, Yuna and Kim, Seok-Mo and Choi, Kyung Hwa and Park, Juhee and Yoon, Hyemee and Park, Keunwan and Park, Ki Cheong and Hur, Cheolgoo},
title = {Exploiting Macropinocytosis Drives Redox Vulnerability to Preferentially Target Drug-Resistant Cancer},
journal = {ACS Nano},
year = {2026},
volume = {20},
number = {29},
pages = {20623--20638},
doi = {10.1021/acsnano.6c04236}
}
EUVIMED